Abstract: The present invention concerns compounds derived from quinoline and quinoxaline, their preparation and their uses, particularly in the field of therapeutics and vaccines or for developing active compounds. The inventive compounds are of general formula (I), and their pharmaceutically acceptable salts.

Abstract: The invention concerns the use of PDE2 inhibitors for treating disorders of the central and peripheral nervous system, a method for therapeutic treatment by administering to an animal said inhibitors. More specifically, the invention concerns novel benzodiazepinone derivatives and their uses in therapeutics more particularly for treating pathologies involving activity of a cyclic nucleotide phosphodiesterase type 2. The invention also concerns methods for preparing same and novel synthesis intermediates.

Abstract: A novel class of pyridazine compositions and related methods of use.

Abstract: The invention concerns drug precursors with antimalarial effect, characterised in that it consists in quaternary bis-ammonium salts of general formula (I) wherein A and A?, identical or different, are respectively either a group A1 and A?1 of formula (1) wherein n=2 to 4; R?1 is hydrogen, C1-C5 alkyl, optionally substituted by an aryl, a hydroxy, an alkoxy, wherein the alkyl comprises 1 to 5 C, or aryloxy and W is halogen or a nucleofuge group; or a group A2 which represents formyl-CHO, or acetyl-COCH3.

Abstract: The invention concerns the field of synthesis organic chemistry applied to the pharmaceutical field and concerns novel derivatives of 4-hydroxybutanoic acid and its higher homologue, 5-hydroxypentanoic acid, their crotonic homologues, pharmaceutical compositions containing them and their pharmaceutical uses. Said novel derivatives are capable of binding with ?-hydroxybutyrate (GHB)-specific receptors and hence capable of exhibiting agonist or antagonist properties, in particular for treating sleep disorders, anxiety and general diseases of the central nervous system. The invention also concerns compounds of general formula (I) wherein the substituents are as defined in the description.

Abstract: The invention concerns novel benzodiazepine derivatives and their uses in the field of therapeutics particularly for treating pathologies involving the activity of a cyclic nucleotide phosphodiesterase. It also concerns methods for preparing them and novel synthesis intermediates.

Abstract: A novel class of pyridazine compositions and related methods of use.

Abstract: Substituted bis-2-aminopyridines of formula (1), wherein Q, R1,R2,R3,R4 are as defined in the specification. A method for preparing said compounds and the use thereof as a drug and in particular as active drugs for controlling parasiticc infections within red blood cells, e.g. malaria or babesiasis.

Abstract: The present invention relates to pyridazine derivatives of formula: ##STR1## which are useful as ligands of cholinergic receptors, in particular, receptors of the M.sub.1 type.

Abstract: The present invention relates to pyridazine derivatives of formula: ##STR1## which are useful as ligands of cholinergic receptors, in particular, receptors of the M.sub.1 type.

Abstract: The invention relates to 3-aminopyridazine derivatives.These compounds have the formula ##STR1## in which: R.sub.V is a linear or branched C.sub.1 -C.sub.4 alkyl group;R.sub.6 is hydrogen, a C.sub.1 -C.sub.3 alkoxy or a hydroxyl group; andZ is a group ##STR2## in which: n.sub.1 and n.sub.2 independently are zero or one,Y.sub.1 and Y.sub.2 independently are hydrogen or a C.sub.1 -C.sub.3 alkyl group, andT is a dialkylamino group in which the alkyls are C.sub.1 -C.sub.3, if Y.sub.1 or Y.sub.2 is other than hydrogen, or T is a heterocycle selected from: ##STR3## Application: drugs active on the central nervous system.

Abstract: A compound having an aryltriazine structure selected from those of formula (I): ##STR1## for which the meaning of the substituents Ar, R.sub.1, R.sub.5, R.sub.6, and R.sub.6 ' is given in the description.The compound of the invention is useful as medicinal product for disorders associated with a cholinergic dysfunction.

Abstract: New imidazo [1,2-c] quinazoline compounds useful as coronary smooth muscle relaxants and corresponding to the formula: ##STR1## in which: Y is oxygen or sulfur;R.sub.1 is (C.sub.1 -C.sub.6) alkyl optionally substituted by a phenyl itself optionally substituted, a (C.sub.3 -C.sub.6) cycloalkyl, optionally substituted phenyl, furyl, thienyl or acyl;R.sub.2 is hydrogen, a halogen or a (C.sub.1 -C.sub.6) alkyl optionally substituted by amino or dialkylamino;R.sub.3 is hydrogen, (C.sub.1 -C.sub.6) alkyl optionally substituted by an aryl, or R--CO--(CH.sub.2).sub.n -- [n being 1, 2 or 3, and R being (C.sub.1 -C.sub.6) alkoxy, amino, (alkyl or dialkyl)amino, morpholino or methylpiperazinyl]; andX is hydrogen or a halogen.These compounds and their physiologically tolerated salts can be used in medical treatment of coronary smooth-muscle dysfunctions.

Abstract: The invention relates to novel tricyclic derivatives which are agonists of cholinergic receptors.These derivatives have the formula ##STR1## in which X=O, S, --OCH.sub.2 -- or --SCH.sub.2 --; R.sub.1 =H or halogen; and R.sub.2 = ##STR2## in which Alk is an alkylene group and R.sub.3, an R.sub.4, which are identical or different, are hydrogen or a lower alkyl group, or R.sub.3 and R.sub.4, with the nitrogen atom to which they are bonded, form a 5- or 6-membered cyclic amino group optionally containing a second heteroatom; or R.sub.2 is a group ##STR3## where R.sub.5 =C.sub.1 -C.sub.4 -alkyl. Application: agonists of cholinergic receptors.

Abstract: The invention relates to novel tricyclic derivatives which are agonists of cholinergic receptors and to drugs containing them.These derivatives have the following formula: ##STR1## in which: X represents a group (CH.sub.2).sub.n, n representing an integer equal to 2, 3 or 4, or alternatively a vinylene group or a methylvinylene group;R.sub.1 and R.sub.2, considered independently, represent hydrogen or a substituent occupying one of the free positions of the benzene ring and selected from the group comprising halogens, a lower alkyl group, a lower alkoxy group, a hydroxyl group, a thiol group, a nitro group and an optionally substituted amino group;Y represents oxygen, sulfur or a group --NH--; andR.sub.3 is an amino groupApplication: agonists of the cholinergic receptors.

Abstract: The present invention relates to imidazo[1,2-b]-pyridazines having the formula: ##STR1## in which: R.sub.1 represents hydrogen, a halogen atom, a C.sub.1 -C.sub.4 alkoxy group or a C.sub.1 -C.sub.4 alkyl group occupying one of the free positions of the benzene ring; R.sub.2 represents hydrogen, a C.sub.1 -C.sub.4 alkyl group or a phenyl group; R.sub.3 denotes hydrogen, a C.sub.1 -C.sub.4 alkyl group or a phenyl group; and R.sub.4 R.sub.5 represent hydrogen or a C.sub.1 -C.sub.4 alkyl group, or R.sub.4 and R.sub.5 form, together with the nitrogen atom to which they are bonded, a 5-membered or 6-membered heterocycle optionally containing a second heteroatom. Application: drugs, especially for the treatment of cortical cholinergic deficiencies.

Abstract: The invention relates to 1,2,4-triazolo [4,3-b]pyridazines substituted in the 7-position of formula: ##STR1## in which R represents hydrogen, a lower alkyl group, a phenyl group, a chlorophenyl group or a benzyl group and R.sub.1 represents a phenyl, halogenophenyl, trifluoromethylphenyl, lower alkyl-phenyl or lower alkoxy-phenyl group or a phenyl-lower alkyl group, or one of its pharmaceutically acceptable salts.Said compounds antagonize the effects of benzodiazepines and therefore are useful as antidotes in the abuse of benzodiazepines and compounds acting on benzodiazepine receptors.